{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:29:36Z","timestamp":1772720976783,"version":"3.50.1"},"publisher-location":"New York, NY","reference-count":25,"publisher":"Springer US","isbn-type":[{"value":"9781071606674","type":"print"},{"value":"9781071606681","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-1-0716-0668-1_21","type":"book-chapter","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T13:08:25Z","timestamp":1598620105000},"page":"281-294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["In Vitro Synthesis of Modified RNA for Cardiac Gene Therapy"],"prefix":"10.1007","author":[{"given":"Nishat","family":"Sultana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Tofael Kabir","family":"Sharkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoav","family":"Hadas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Chepurko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lior","family":"Zangi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,29]]},"reference":[{"issue":"3","key":"21_CR1","first-page":"e28","volume":"129","author":"AS Go","year":"2014","unstructured":"Go AS et al (2014) Heart disease and stroke statistics\u20142014 update: a report from the American Heart Association. Circulation 129(3):e28\u2013e292","journal-title":"Circulation"},{"issue":"Suppl 2","key":"21_CR2","first-page":"ii3","volume":"91","author":"H Dargie","year":"2005","unstructured":"Dargie H (2005) Heart failure post-myocardial infarction: a review of the issues. Heart 91(Suppl 2):ii3\u2013ii6. discussion ii31, ii43-8","journal-title":"Heart"},{"issue":"4","key":"21_CR3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ymthe.2018.11.018","volume":"27","author":"A Magadum","year":"2019","unstructured":"Magadum A, Kaur K, Zangi L (2019) mRNA-based protein replacement therapy for the heart. Mol Ther 27(4):785\u2013793","journal-title":"Mol Ther"},{"issue":"10","key":"21_CR4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin U, Kariko K, Tureci O (2014) mRNA-based therapeutics\u2014developing a new class of drugs. Nat Rev Drug Discov 13(10):759\u2013780","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"21_CR5","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/mt.2011.67","volume":"19","author":"RS McIvor","year":"2011","unstructured":"McIvor RS (2011) Therapeutic delivery of mRNA: the medium is the message. Mol Ther 19(5):822\u2013823","journal-title":"Mol Ther"},{"issue":"11","key":"21_CR6","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Kariko","year":"2008","unstructured":"Kariko K et al (2008) Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 16(11):1833\u20131840","journal-title":"Mol Ther"},{"issue":"10","key":"21_CR7","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/nbt.2682","volume":"31","author":"L Zangi","year":"2013","unstructured":"Zangi L et al (2013) Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol 31(10):898\u2013907","journal-title":"Nat Biotechnol"},{"key":"21_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.omtn.2018.08.021","volume":"13","author":"A Magadum","year":"2018","unstructured":"Magadum A et al (2018) Ablation of a single N-glycosylation site in human FSTL 1 induces cardiomyocyte proliferation and cardiac regeneration. Mol Ther Nucleic Acids 13:133\u2013143","journal-title":"Mol Ther Nucleic Acids"},{"issue":"6","key":"21_CR9","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.ymthe.2017.03.016","volume":"25","author":"N Sultana","year":"2017","unstructured":"Sultana N et al (2017) Optimizing cardiac delivery of modified mRNA. Mol Ther 25(6):1306\u20131315","journal-title":"Mol Ther"},{"issue":"3","key":"21_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1172\/JCI0214364","volume":"109","author":"A Heiser","year":"2002","unstructured":"Heiser A et al (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109(3):409\u2013417","journal-title":"J Clin Invest"},{"issue":"1","key":"21_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1385\/IJGC:32:1:1","volume":"32","author":"MA Morse","year":"2002","unstructured":"Morse MA et al (2002) The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int J Gastrointest Cancer 32(1):1\u20136","journal-title":"Int J Gastrointest Cancer"},{"issue":"3","key":"21_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1081\/CNV-120018224","volume":"21","author":"MA Morse","year":"2003","unstructured":"Morse MA et al (2003) Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Investig 21(3):341\u2013349","journal-title":"Cancer Investig"},{"issue":"5","key":"21_CR13","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/mt.2010.289","volume":"19","author":"SM Rittig","year":"2011","unstructured":"Rittig SM et al (2011) Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther 19(5):990\u2013999","journal-title":"Mol Ther"},{"issue":"6","key":"21_CR14","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.4049\/jimmunol.174.6.3798","volume":"174","author":"Z Su","year":"2005","unstructured":"Su Z et al (2005) Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 174(6):3798\u20133807","journal-title":"J Immunol"},{"issue":"5","key":"21_CR15","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/CJI.0b013e3181a00068","volume":"32","author":"B Weide","year":"2009","unstructured":"Weide B et al (2009) Direct injection of protamine-protected mRNA: results of a phase 1\/2 vaccination trial in metastatic melanoma patients. J Immunother 32(5):498\u2013507","journal-title":"J Immunother"},{"issue":"10","key":"21_CR16","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1093\/annonc\/mdt245","volume":"24","author":"S Wilgenhof","year":"2013","unstructured":"Wilgenhof S et al (2013) A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol 24(10):2686\u20132693","journal-title":"Ann Oncol"},{"issue":"12","key":"21_CR17","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1038\/mt.2010.146","volume":"18","author":"RJ Creusot","year":"2010","unstructured":"Creusot RJ et al (2010) A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice. Mol Ther 18(12):2112\u20132120","journal-title":"Mol Ther"},{"issue":"5","key":"21_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1089\/hum.2007.115","volume":"19","author":"DA Mitchell","year":"2008","unstructured":"Mitchell DA et al (2008) Selective modification of antigen-specific T cells by RNA electroporation. Hum Gene Ther 19(5):511\u2013521","journal-title":"Hum Gene Ther"},{"issue":"8","key":"21_CR19","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/jgm.1214","volume":"10","author":"K Okumura","year":"2008","unstructured":"Okumura K et al (2008) Bax mRNA therapy using cationic liposomes for human malignant melanoma. J Gene Med 10(8):910\u2013917","journal-title":"J Gene Med"},{"issue":"2","key":"21_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/mt.2012.250","volume":"21","author":"Y Wang","year":"2013","unstructured":"Wang Y et al (2013) Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther 21(2):358\u2013367","journal-title":"Mol Ther"},{"issue":"5","key":"21_CR21","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/mt.2012.7","volume":"20","author":"K Kariko","year":"2012","unstructured":"Kariko K et al (2012) Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol Ther 20(5):948\u2013953","journal-title":"Mol Ther"},{"issue":"2","key":"21_CR22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/nbt.1733","volume":"29","author":"MS Kormann","year":"2011","unstructured":"Kormann MS et al (2011) Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 29(2):154\u2013157","journal-title":"Nat Biotechnol"},{"issue":"3","key":"21_CR23","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1172\/JCI65351","volume":"123","author":"LE Mays","year":"2013","unstructured":"Mays LE et al (2013) Modified Foxp3 mRNA protects against asthma through an IL-10-dependent mechanism. J Clin Invest 123(3):1216\u20131228","journal-title":"J Clin Invest"},{"issue":"6","key":"21_CR24","doi-asserted-by":"publisher","first-page":"e003293","DOI":"10.1161\/JAHA.112.003293","volume":"1","author":"O Zimmermann","year":"2012","unstructured":"Zimmermann O et al (2012) Successful use of mRNA-nucleofection for overexpression of interleukin-10 in murine monocytes\/macrophages for anti-inflammatory therapy in a murine model of autoimmune myocarditis. J Am Heart Assoc 1(6):e003293","journal-title":"J Am Heart Assoc"},{"key":"21_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-1-4939-6588-5_8","volume":"1521","author":"J Kondrat","year":"2017","unstructured":"Kondrat J, Sultana N, Zangi L (2017) Synthesis of modified mRNA for myocardial delivery. Methods Mol Biol 1521:127\u2013138","journal-title":"Methods Mol Biol"}],"container-title":["Methods in Molecular Biology","Cardiac Regeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-0668-1_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T03:27:15Z","timestamp":1619321235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-0668-1_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,29]]},"ISBN":["9781071606674","9781071606681"],"references-count":25,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-0668-1_21","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,29]]},"assertion":[{"value":"29 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}